Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07623642 GV20-0251 MSS/pMMR/MSI-L Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07623642 clinical trial report covering GV20-0251, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07624487 Pemetrexed Dipotassium Adenocarcinoma of Lung Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07624487 clinical trial report covering Pemetrexed Dipotassium, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07622550 Serplulimab Metastatic Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07622550 clinical trial report covering Serplulimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07622186 Carboplatin Non-Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07622186 clinical trial report covering Carboplatin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07624045 Incobotulinum toxinA (Biotecon) Piriformis Muscle Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07624045 clinical trial report covering Incobotulinum toxinA (Biotecon), Phase 2, endpoints, sponsor, geography, readout timing and development white space
Latest Hotspot
8 min read
NCT07623460 Zanzalintinib Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07623460 clinical trial report covering Zanzalintinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07625553 R2R01 Acute Kidney Injury Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07625553 clinical trial report covering R2R01, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262220 Igermetostat Advanced Prostate Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
CTR20262220 clinical trial report covering Igermetostat, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07627464 Anlotinib Dihydrochloride Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07627464 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07625293 Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isola Crohn Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07625293 clinical trial report covering Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isola, Phase 2, endpoints, sponsor, geog
Latest Hotspot
8 min read
NCT07626541 Fructose Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07626541 clinical trial report covering Fructose, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07625891 Nomelcitinib Nonsegmental vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07625891 clinical trial report covering Nomelcitinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.